Aprea Therapeutics completes its series C investment round with EUR 5M from Janus Henderson Investors.
Aprea Therapeutics, a Boston, Massachusetts- and Stockholm, Sweden-based clinical-stage biotechnology company developing novel anticancer therapies targeting the p53 tumor suppressor protein, announced that funds managed by Janus Henderson Investors has joined its Series C financing as a new investor, raising the total amount of the financing from EUR 50 to EUR 55 million.
Janus Henderson Investors joins the financing round closed in November, 2018 and led by Redmile Group, with participation by Rock Springs Capital and existing investors: 5AM Ventures, Versant Ventures, HealthCap, Sectoral Asset Management and Karolinska Development AB.
Proceeds from the financing will be used to advance the clinical development of APR-246, a first-in-class anticancer agent that reactivates mutated p53 tumor suppressor protein. Aprea has commenced a Phase 3 clinical study in myelodysplastic syndromes (MDS) and has completed enrollment in a Phase Ib/II clinical trial in p53 mutated high-risk myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia (AML) with APR-246 and azacitidine. Additional studies in MDS and AML are underway and in planning with other approved agents.